Neuroscience
The Ultimate Cure
by David Ewing Duncan
CondeNast Portfolio
May 2008
"The neurotech industry is engaged in a $2 trillion race to fix your brain. Many players will fail, but the payoff will be huge for those who succeed."
[snip]
"Neurotech’s returns are already enormous. In 2006, the industry brought in more than $120 billion—about $101 billion from drugs and the rest from neurodevices ($4.5 billion) and neurodiagnostics ($15 billion)—up 10 percent from the previous year, reports NeuroInsights, a market research and investment advisory firm. But industry analysts insist that this figure hardly begins to suggest the potential. For Alzheimer’s, a disease currently without an effective treatment for about 4.5 million sufferers in the U.S., 40 companies—including behemoths like Eli Lilly, GlaxoSmithKline, and Wyeth, as well as Targacept and a gaggle of similar upstarts—are testing 48 new drugs in human trials in a quest for the Prozac of dementia. The push has brought many small to midsize biotech firms together in partnerships with larger pharmaceutical companies to pursue everything from pain-control compounds derived from chili peppers to an antistroke medicine developed from vampire-bat saliva. There is so much activity in neurotech that last fall it got its own index, NERV, on the Nasdaq, tracking the performance of 30 leading brain companies based in the United States. Analysts estimate that the sector should continue to grow by about 10 percent a year, which would produce a brain-industrial complex worth more than $300 billion in the next 10 years."
[snip]
[ ... Read the full article ... ]
- Why You Should Invest In Shares With Simple Names
When it comes to predicting short-term share price fluctuations, it appears a simple psychological explanation has succeeded where countless complex economic theories have failed. The human tendency to respond positively to easily processed information...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Business World: "the Brain Industry"
From The Seattle Times:Biotech Watch: Biotech companies scramble to develop brain-related products By Steve Johnson Knight Ridder Newspapers The Seattle Times Monday, July 25, 2005 SAN JOSE, Calif. — The prospect of a billion people nearing the age...
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375)
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:New entries shake insomnia market's slumber Reuters ...
Neuroscience
Analysis of the Neurotechnology Industry
The Ultimate Cure
by David Ewing Duncan
CondeNast Portfolio
May 2008
"The neurotech industry is engaged in a $2 trillion race to fix your brain. Many players will fail, but the payoff will be huge for those who succeed."
[snip]
"Neurotech’s returns are already enormous. In 2006, the industry brought in more than $120 billion—about $101 billion from drugs and the rest from neurodevices ($4.5 billion) and neurodiagnostics ($15 billion)—up 10 percent from the previous year, reports NeuroInsights, a market research and investment advisory firm. But industry analysts insist that this figure hardly begins to suggest the potential. For Alzheimer’s, a disease currently without an effective treatment for about 4.5 million sufferers in the U.S., 40 companies—including behemoths like Eli Lilly, GlaxoSmithKline, and Wyeth, as well as Targacept and a gaggle of similar upstarts—are testing 48 new drugs in human trials in a quest for the Prozac of dementia. The push has brought many small to midsize biotech firms together in partnerships with larger pharmaceutical companies to pursue everything from pain-control compounds derived from chili peppers to an antistroke medicine developed from vampire-bat saliva. There is so much activity in neurotech that last fall it got its own index, NERV, on the Nasdaq, tracking the performance of 30 leading brain companies based in the United States. Analysts estimate that the sector should continue to grow by about 10 percent a year, which would produce a brain-industrial complex worth more than $300 billion in the next 10 years."
[snip]
[ ... Read the full article ... ]
- Why You Should Invest In Shares With Simple Names
When it comes to predicting short-term share price fluctuations, it appears a simple psychological explanation has succeeded where countless complex economic theories have failed. The human tendency to respond positively to easily processed information...
- Alzheimer's: Bapineuzumab And Solanezumab
Survey shows dim faith in Lilly, Pfizer Alzheimer's drugs Ransdell Pierson | Reuters The Chicago Tribune June 19, 2012 [snip] "Results from the survey of 146 investors were released late on Tuesday by Mark Schoenebaum, a pharmaceutical analyst for...
- Business World: Myriad Genetics, Flurizan (mpc-7869), And Alzheimer Disease
From the AP, via Yahoo! News: Largest-Ever Alzheimer's Drug Trial Begins By PAUL ELIAS, AP Biotechnology Writer Sun Mar 12, 6:58 AM ET SAN FRANCISCO - It's tragedy enough that Pat Williams' mother...
- Business World: "the Brain Industry"
From The Seattle Times:Biotech Watch: Biotech companies scramble to develop brain-related products By Steve Johnson Knight Ridder Newspapers The Seattle Times Monday, July 25, 2005 SAN JOSE, Calif. — The prospect of a billion people nearing the age...
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375)
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:New entries shake insomnia market's slumber Reuters ...